Cargando…

Angiotensin in ECMO patients with refractory shock

Detalles Bibliográficos
Autores principales:	Ostermann, Marlies, Boldt, David W., Harper, Michael D., Lim, George W., Gunnerson, Kyle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211436/ https://www.ncbi.nlm.nih.gov/pubmed/30382926 http://dx.doi.org/10.1186/s13054-018-2225-4

Ejemplares similares

Postcardiotomy VA-ECMO for refractory cardiogenic shock
por: Charlesworth, Michael, et al.
Publicado: (2017)

Acute kidney injury in ECMO patients
por: Ostermann, Marlies, et al.
Publicado: (2021)

Angiotensin II in ECMO patients: a word of caution
por: Antonucci, Elio, et al.
Publicado: (2019)

Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial
por: Ham, Kealy R., et al.
Publicado: (2019)

Should ECMO be used in cardiogenic shock?
por: Gokalp, Orhan, et al.
Publicado: (2019)

The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature
por: Busse, Laurence W., et al.
Publicado: (2017)

ECMO in paediatric septic shock: an urgent need for prospective trial
por: Beretta-Piccoli, Xavier, et al.
Publicado: (2020)

ECMO Support in Refractory Cardiogenic Shock: Risk Factors for Mortality
por: Rajsic, Sasa, et al.
Publicado: (2022)

Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock
por: Bellomo, Rinaldo, et al.
Publicado: (2020)

Do we need another prognostic score for cardiogenic shock patients with ECMO?
por: Champion, Sébastien
Publicado: (2017)

Refractory vasodilatory shock secondary to metformin overdose supported with VA ECMO()
por: Ives Tallman, Crystal, et al.
Publicado: (2021)

Angiotensin in Critical Care
por: Hall, Anna, et al.
Publicado: (2018)

Blood lactate normalization following venoarterial ECMO institution for refractory cardiogenic shock
por: Bottiroli, M, et al.
Publicado: (2015)

In-hospital and long-term mortality after venoarterial ECMO for refractory cardiogenic shock
por: Bottiroli, M, et al.
Publicado: (2015)

Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial
por: Wieruszewski, Patrick M., et al.
Publicado: (2023)

ECMO and the intensivist
por: Ghio, F E, et al.
Publicado: (2011)

Angiotensin II for the treatment of vasodilatory shock: enough data to consider angiotensin II safe?
por: Buchtele, Nina, et al.
Publicado: (2018)

Predicting Survival After VA-ECMO for Refractory Cardiogenic Shock: Validating the SAVE Score
por: Amin, Faizan, et al.
Publicado: (2020)

Angiotensin II in vasodilatory shock: lights and shadows
por: Antonucci, Elio, et al.
Publicado: (2017)

Extracorporeal membrane oxygenation (ECMO) for critically ill adults in the emergency department: history, current applications, and future directions
por: Mosier, Jarrod M., et al.
Publicado: (2015)

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II
por: Tumlin, James A., et al.
Publicado: (2018)

Cytokine adsorption in severe, refractory septic shock
por: Wendel Garcia, Pedro David, et al.
Publicado: (2021)

Outcomes of patients with refractory out-of-hospital cardiac arrest transported to an ECMO centre compared with transport to non-ECMO centres
por: Bernard, Stephen A., et al.
Publicado: (2023)

Angiotensin II: a new approach for refractory shock management?
por: Kimmoun, Antoine, et al.
Publicado: (2014)

ECMO in cardiac arrest and cardiogenic shock
por: Napp, L. C., et al.
Publicado: (2017)

ECMO for COVID-19 patients in Europe and Israel
por: Lorusso, Roberto, et al.
Publicado: (2021)

Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial
por: Bellomo, Rinaldo, et al.
Publicado: (2020)

Extracorporeal Membrane Oxygenation (ECMO) for Refractory Cardiac Arrest
por: Hanneken, Kevin, et al.
Publicado: (2020)

Angiotensin II Use in Refractory Multisystem Shock: A Case Report
por: Ahmed, Mohamed, et al.
Publicado: (2018)

Concomitant Use of VA-ECMO and Impella Support for Cardiogenic Shock
por: Modi, Shan P., et al.
Publicado: (2023)

Use of ECMO for Cardiogenic Shock in Pediatric Population
por: Bhaskar, Priya, et al.
Publicado: (2021)

Renal failure in the intensive care unit: acute kidney injury compared to end-stage renal failure
por: Ostermann, Marlies, et al.
Publicado: (2008)

Vasopressor-Refractory Shock From Clozapine Overdose Treated With Synthetic Angiotensin II Infusion
por: Wieruszewski, Patrick M., et al.
Publicado: (2020)

Early hyperoxia and 28-day mortality in patients on venoarterial ECMO support for refractory cardiogenic shock: discussion about potential confounding factors
por: Winiszewski, Hadrien, et al.
Publicado: (2022)

Broad spectrum vasopressors: a new approach to the initial management of septic shock?
por: Chawla, Lakhmir S., et al.
Publicado: (2019)

Appraisal of fungal infections during ECMO therapy
por: Mongardon, Nicolas, et al.
Publicado: (2018)

Role of VA ECMO in septic shock: Does it work?
por: Combes, Alain
Publicado: (2017)

ECMO and endogenous carboxyhemoglobin formation
por: Tripathi, Ravi S, et al.
Publicado: (2011)

Veno-venous ECMO indications: more than respiratory support
por: Blandino Ortiz, Aaron, et al.
Publicado: (2019)

Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock?
por: Bendjelid, Karim
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8tjm9pul3q53177880hq43h5fk